179 |
Axxess Plus™: The First Drug-Eluting Stent for the Treatment of Bifurcation Lesions |
Jeffrey W. Moses |
May. 19. 06 |
178 |
Percutaneous Interventions for Patent Foramen Ovale |
Eric Eeckhout |
Oct. 06. 05 |
177 |
New Concept and Device for Ostial and Bifurcation Stenting |
Yaron Almagor |
Oct. 06. 05 |
176 |
The E-valve Edge-to-Edge Repair for Mitral Regurgitation: Design Concept and EVEREST Update |
Ted Feldman |
Oct. 06. 05 |
175 |
Drug-Eluting Stents, Late Loss, and Restenosis DES to Prevent MIs |
Richard E. Kuntz |
Sep. 29. 05 |
174 |
What Are the Proper End Points for DES Trials? |
Alan C. Yeung |
Sep. 29. 05 |
173 |
Plaque Progression and Regression |
James R. Margolis |
Sep. 29. 05 |
172 |
Evidence-Based Medicine Analysis of Current DES Clinical Use Guidelines: A Roadmap for Clinicians |
Gregg W. Stone |
Sep. 29. 05 |
171 |
Preventative Effects of Rosiglitazone on Restenosis after Coronary Stent Implantation |
Donghoon Choi |
Sep. 23. 05 |
170 |
The Promise of the Thiazolidinediones in the Management of Type 2 Diabetes-Associated Cardiovascular Disease |
Stephen Alistair Smith |
Sep. 23. 05 |